XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, is reporting on the market and product development of its Rotigotine transdermal (“TDS”) patch, which is designed for the treatment of Parkinson’s disease (“PD”) and restless legs syndrome (“RLS”). XPhyto’s Rotigotine patch features the TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH (“Vektor”). Because the active pharmaceutical ingredient is not well absorbed when administered orally, the TDS patch is designed to increase bioavailability, providing a consistent supply of the substance during a 24-hour period. The company reports that global sales for the patches totaled approximately $518 million in 2021 with the market expected to surpass $766 million by 2030. The company also noted that, based on the success of its European-based human bioavailability study completed last year, it is advancing the product toward a final pivotal study later this year and, depending on the results of that study, may apply for regulatory approval. The company also anticipates releasing the results of a skin permeation study it has conducted at Vektor’s EU GMP laboratory and manufacturing facility in Baden-Württemberg, Germany, in the coming weeks. Vektor is a German narcotics manufacturer, developer and researcher that has become a leader in the design, testing and manufacture of innovative, no-invasive drug-delivery systems.
To view the full press release, visit https://ibn.fm/Md9L6
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and the manufacture, standardization, and evaluation of psychedelic compounds for the treatment of neurological conditions. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
